Intervet/Schering-Plough has launched Vectin chewable tablets, an ivermectin wormer for horses which is administered as a treat straight from the hand rather than in the traditional paste or granule formulation.
According to the company, syringe handling, horse acceptance and the tendency to spit out some or all of the paste are common problems reported by owners when worming their horses, and more than 55% admit that these issues can result in a mixture of emotions, including frustration, anxiety and upset.
Field studies with Vectin showed more than 70% spontaneous acceptance by horses and the simple calculation of one tablet for every 110kg of a horse or foal's bodyweight helps to reduce wastage as unused tablets can be stored away for future use.
Pharmacokinetics studies have demonstrated improved bioavailability (AUC) and maximal concentration (Cmax) when compared with an equivalent competitor ivermectin paste formulation. Trials have also shown that a more consistent blood concentration of ivermectin when given as a chew which could potentially limit the chance of inducing resistance.
Intervet/Schering Plough says that used as part of a strategic worming plan, Vectin chewable tablets control potentially a wide range of endoparasites including small and large strongyles, stomach worms, cutaneous worms and stomach bots.
Vectin chewable tablets are available as a seven-tablet blister pack, perfect for treating a horse or a couple of ponies. For yards, a tub of 60 tablets is available, containing enough to dispense product for worming approximately 12 horses.
Vectin chewable tablets are recommended for use alongside Pyratape P and Panacur in Intervet/Schering-Plough Animal Health's Active3 worming plan, a strategic three-year approach to rotating wormers in order to minimize the risk of resistance developing. Visit http://www.intervet.co.uk/ for a copy of the three-year plan.
Elanco Animal Health has highlighted the results of a new study1 which concludes that Duvaxyn IE-T Plus stimulates a highter protective antibody response than four other equine influenza vaccines commercially available in Ireland.
The trial compared the antibody responses of unvaccinated Thoroughbred weanlings following primary vaccination with Duvaxyn IE-T Plus, Equilis Resequin, Equip FT, Equilis Prequenza Te and ProteqFlu Te.
In addition, following the first vaccination, 43% of the weanlings failed to seroconvert. However, amongst those vaccinated with Duvaxyn IE-T Plus a 100% response rate was observed. The failure rate amongst vaccines other than Duvaxyn IE-T Plus ranged between 7.7% and 78.6%. By the time of the third vaccination (31 weeks after the first) all horses had responded to vaccination.
The study, conducted by the Irish Equine Centre in Johnstone, the Department of Life Sciences at the University of Limerick and the Department of Statistics at Trinity College in Dublin, involved 66 unvaccinated Thoroughbred weanlings on four different stud farms. Following primary vaccination (V1, V2 and V3) with the five vaccines antibody responses were monitored for six months post V3 by single radial haemolysis. Elanco says that the correlation between SRH antibody levels and protection has been well-established and accepted2.
Elanco also highlights a recent study3 which it says demonstrated the ability of Duvaxyn IE-T Plus equine influenza vaccine to cross protect against A/equi-2/Richmond/1/07 (H3N8) two weeks after a two dose primary course. The company says that this is believed to be the first demonstration of cross protection by a current UK equine influenza vaccine against a Florida sub-lineage clade 2 reference strain.
Anna Jackson, national veterinary manager for Elanco Companion Animal Health said: "Most studies carried out by vaccine companies take place under controlled conditions that are optimal for effective vaccination. This latest study shows how well Duvaxyn IET plus stimulates immunity under field conditions against both vaccinal and non-vaccinal strains. Importantly, all the weanlings vaccinated with Duvaxyn seroconverted after the first vaccination, conferring earliest and most reliable protection for these vulnerable animals."
For further information please contact your local Elanco Companion Animal Health key account manager or phone 01256 779881.
References:
Defra Minister David Heath has announced the latest bute (phenylbutazone) test results. The presence of bute has been confirmed in 8 samples out of 206 tests.
Chief Medical Officer Professor Dame Sally Davies has stated that horsemeat containing phenylbutazone presents a very low risk to human health.
Responding to these latest developments the British Veterinary Association (BVA) and British Equine Veterinary Association (BEVA) have issued the following statement:
"The presence of phenylbutazone (or bute) in horses intended for the food chain will be of concern to consumers who rightly expect the UK food chain to be robust. We are grateful to the Chief Medical Officer for clarifying the very low level of risk that this presents to human health and we will work with the FSA and Defra in any way we can to assist their investigations into these incidents.
"The ability to treat horses with bute is very important for equine welfare. Bute provides affordable, long-term pain relief for horses and is unique in this respect.
"The UK Horse Passport Regulations are designed to facilitate the ongoing medical treatment of horses not intended for the human food chain, whilst ensuring that these animals do not enter the food chain.
"We fully support the concept of the Horse Passport Regulations but have argued for some time that there are problems with the system in terms of the number of Passport Issuing Authorities and the vulnerability of the system to fraud. We are very keen to continue our dialogue with Defra and others to find ways to make the system more robust.
"Our members are aware of the strict rules regarding the regulation of medicines (including bute) and the use of horse passports, and in recent years we have provided clear guidance on the regulations to help both vets and their clients. These incidents will hopefully reinforce these messages amongst horse owners and all of us involved in equine healthcare."
Guidance notes are available via the BEVA website Medicines Page (http://www.beva.org.uk/useful-info/Vets/Guidance/Medicines)
Equine charity The Horse Trust has reported an unprecendented number of enquiries from people wanting to rehome their horses and ponies.
In the three weeks since the financial crisis resulted in repossessions, job losses and cash shortages, more than 500 people made inquiries about having their horses rescued or rehomed.
Susan Lewis, The Horse Trust's marketing manager said: "There is a new generation of horses which is being affected in this way. Animals which have been cherished for 20 years and are now approaching retirement age are becoming too expensive for owners to maintain at livery - especially as the winter season is approaching with its inherent requirements for additional feed, housing and veterinary care."
She added: "Most people are saying: 'Help, what can I do? I adore my horse which has lived with me since I was a tiny child - but now I can barely feed myself let alone my horse. He has always come first - but having lost my home and the field in which I keep him, I just don't know where to turn'.
"It isn't a new story - and we have for many years warned horse owners that they face the issues of cost, care and commitment well into the old age of a horse, which can be up to 30 years. Now, however, it seems that we are facing a more widespread crisis."
Like most other horse charities, the Trust's Home of Rest for horses is full to capacity.
"We simply can't take on any other animals," said Susan. "The charity pound is now stretched to breaking point as people's purses dry up - and with rising feed prices and veterinary charges, it now costs more than £17 a day to keep a horse here.
Fort Dodge Animal Health has announced it is working with the authorities to put measures in place to make its West Nile Virus vaccine, licensed in the United States, available to the European equine market. These measures will ensure a vaccine is readily available in the event of an outbreak in the UK.
This news comes as the Zooprophylactic Institute of Teramo, the Italian National Reference Centre for Exotic Diseases, has confirmed an outbreak of WNV among horses in stables in the northern province of Ferrara. About 20 horses are believed to have been affected.
Fort Dodge was the first company to develop and fully license a vaccine to protect horses against this potentially deadly disease. An inactivated whole virus vaccine, it was the only vaccine available in the United States at the height of the 2002 outbreak, which affected 15,000 horses. The U.S. Department of Agriculture credited the vaccine with contributing to the 70 per cent decline in U.S. equine West Nile cases since the height of the outbreak. WNV is now considered endemic in all areas of North America.
"As this latest outbreak of WNV in Italy highlights, the disease presents an increasing threat to the equestrian sector in Europe," says Helen Barnes, EMEA Equine Business Manager for Fort Dodge. "With little current natural immunity among the equine population, the consequences of a major outbreak could be devastating."
"Until now, horse owners in Europe have perhaps believed WNV is not a disease they should be concerned with but the outbreak in Ferrara came out of the blue, and at a time when a human case of WNV was also reported in the same province. This situation of both human and equine cases being reported is identical to that seen in the outbreaks in the United States. It's a stark reminder of the challenge this disease poses, particularly as environmental factors, such as global warming and heavy rains threaten to create mass breeding grounds for mosquitoes," says Barnes.
"Our experience with WNV in the United States has given us an exceptional understanding of the disease and the importance of vaccination. We now look forward to working in partnership with the European governments, the EU Commission and the veterinary community across Europe to help build understanding and knowledge of this dangerous emerging disease threat."
Chanelle has announced the launch of Ketamidor 100 mg/ml Solution for Injection (ketamine), licensed for use in cats, dogs, horses, cattle and swine in the UK and Ireland.
The company says the new product provides a versatile addition to anaesthetic regimes. It can be used in combination with other widely-used anaesthetics and sedatives. Chanelle says it also has analgesic properties that make it particularly beneficial to include in anaesthetic protocols when carrying out painful surgical procedures.
Ketamidor 100mg/ml Solution for Injection has a zero day withdrawal period for milk and meat when used in cattle and pigs, allowing high welfare standards to be maintained without compromising economic returns.
According to Chanelle, ketamine is now experiencing a resurgence of interest as its analgesic properties and minimal impact on spontaneous respiration become increasingly appreciated.1
Angela Wilkin, Chanelle UK's Sales and Marketing Manager said: "Ketamidor makes a great addition to our portfolio of pain management products. Our territory managers are looking forward to speaking to those vets who are already accustomed to using ketamine and those that may be considering adding it to their current protocols."
Reference
Current World Organisation for Animal Health (OIE) recommendations are to include a representative strain from each of the two sublineages of equine influenza virus (EIV) - Florida Clade 1 and Florida Clade 2, to deliver optimum protection.
MSD's study was designed to evaluate the efficacy of Equilis Prequenza, containing whole virus Newmarket/2/93 (European strain) and South Africa/4/03 (Clade1) EIV strains, and an HA canarypox vectored vaccine containing Florida Clade 1 and Clade 2 strains.
Two groups of seven Fjord ponies were vaccinated twice, 4 weeks apart (V1 on day 0 and V2 on day 28). One group was vaccinated with Equilis Prequenza (MSD AH) and one group with ProteqFlu (Boehringer Ingleheim). The protective antibody response was measured and ponies were challenged, along with six unvaccinated control ponies, by experimental infection with Wexford/14 (a heterologous clade 2 strain), 1 20 days (4.5 months) after V2, and clinical signs and virus shedding monitored. EI serology was measured by single radial haemolysis (SRH) and hemagglutination inhibition (HI). Clinical signs and virus shedding (measured by qRT-PCR and egg titration) were compared between groups and with controls.
Vicki Farr, BVetMed MRCVS, equine veterinary advisor at MSD Animal Health said: "Following challenge at 120 days after V2 with Wexford/14, this study demonstrates that both vaccines provide a highly significant degree of protection against clinical signs of EI and viral shedding compared to unvaccinated controls. Although the study was not designed to compare the efficacy of the two vaccines, because of practical limitations on the number of animals and hence low power, there was no evidence of any significant differences between these two groups. There was, however, a trend towards slightly lower clinical score on days 4-8 and reduced virus excretion on days 2-5 in the Equilis Prequenza group compared to the HA canarypox vectored vaccine.”
MSD says Equilis Prequenza offers a broad based approach to immunogenicity by addressing and adapting key areas of an equine influenza vaccine - Matrix-C adjuvant, whole virus antigen and strain; efficacy has been proven through challenge trials and longer term protection confirmed by serology.
Vicki added: "Equilis Prequenza addresses key factors involved in promoting effective immunogenicity. It combines the demonstrated efficacy against challenge, with a current circulating strain with an established safety profile. Equilis Prequenza stimulates active immunity against EI providing the reassurance your clients demand. MSD Animal Health is committed to working with equine practices to improve vaccination rates in at-risk horses."
For more information about the trial results contact your MSD Animal Health account manager.
VetCell Bioscience has become the first UK-based stem cell centre to be authorised under the Veterinary Medicines Regulations.
Following a rigorous series of inspections and reports by Good Manufacturing Practice (GMP) Inspectors VetCell, in conjunction with their UK laboratory partner Biobest, were officially authorised as an equine stem cell centre on 1 October 2009.
David Mountford, Chief Operating Officer of VetCell Bioscience said: "To have received formal authorisation so swiftly reflects the high standard of our operation and our ability to lead the field in the increasingly competitive sector of stem cell technology."
Stem cell therapy involves implanting millions of the animal's own stem cells and autologous growth factors directly into the injured tendon or ligament. The service VetCell Bioscience offers is the collection, storage, processing and supply of stem cells suitable for administration back into the donor animal.
According to the company, there is considerable interest from the human sector and studies in human medicine, for the treatment of Achilles tendinopathies, could begin as early as next year.
The charity will be carrying out a study about the disease in collaboration with the Universities of Liverpool and Nottingham. However, because funding for research is limited, and because researchers want it to answer questions around PPID that owners and veterinary surgeons actually want to know, they are asking for your suggestions.
The AHT says that it wants to provide owners and vets with practical and applicable advice that will improve the wellbeing of their horses, based on scientific evidence. So whether that’s a question around how the disease is diagnosed, the best way to treat it or what the long term prognosis is, now is your chance to have your say.
If you own or care for a horse/pony with PPID or are a veterinary surgeon that treats them (or you have done in the past) please visit: www.aht.org.uk/PPID, to take part.
If you have any questions, contact the Project Investigator Becky Tatum by email: becky.tatum @aht.org.uk or by telephone: 01638 751000 Ext. 1241
According to the company, information on best worming strategies for foals and yearlings remains largely anecdotal, making it difficult to develop a clear plan for this age group. Zoetis veterinary surgeon Wendy Talbot has therefore reviewed the recent literature to develop an eight-point plan.
Explaining the guidance, Wendy writes:
Foals and yearlings are usually more susceptible to worms than are adult horses because they have had little chance to develop any immunity. They are more vulnerable to related diseases and tend to have higher egg shedding, which increases the risk of infection. The main parasitic culprits in the UK for foals less than six months of age are large roundworms (ascarids). In older foals and weanlings, small and large strongyles, tapeworms (and pinworms) are the main considerations.1 Yearlings may also have a second wave of large roundworm infection at 8-10 months of age.2 Any control strategy will need to take into account the individual circumstances such as stocking density, pasture management and previous disease history.
Guidelines for parasite control in foals suggest a first treatment with fenbendazole at 2-3 months of age, targeting large roundworm, followed by another treatment at 5-6 months. Alternatively, pyrantel may be considered for these doses; however, there may be resistance in some areas and foals with large adult ascarid burdens may be at higher risk of intestinal rupture when this drug is used.4 At weaning (approximately six months of age), it is advisable to perform a faecal worm egg count (FWEC) to determine if treatment for strongyles is also required; the macrocyclic lactone anthelmintics (ivermectin or moxidectin) are expected to have the highest efficacy. At 9 and 12 months of age treatment for stronglyes and a larvicidal dose for encysted stages of small strongyles (moxidectin or a 5 day course of fenbendazole) are indicated. A tapeworm treatment should be included with one of these doses.2,3
For yearlings, two methods have recently been proposed for worm control: the first involves using faecal worm egg counts (FWECs) at more frequent intervals than for adults to guide dosing for strongyles in the grazing season.1 The second suggests three baseline treatments targeting strongyles in spring, summer and late autumn, with FWECs in between to identify and treat any still shedding high numbers of eggs, up to a maximum of six treatments per year.2 Macrocyclic lactones have the highest expected efficacy against small strongyles and should form the basis of treatments; however, pyrantel can be considered for some treatments where it has been shown to have continued efficacy. Both strategies include a larvcidal treatment for encysted small redworm combined with testing or treating for tapeworm in late autumn. The inclusion of one or two doses of a macrocyclic lactone each year (usually already used for small strongyle control) should be sufficient to prevent large strongyle related disease.3
The wide differences in the circumstances of foals and yearlings, together with geographical variations in resistance patterns and a lack of consensus on best practice in this group means it is not possible to define a single approach to a worming plan. An important point to note is that FWECs may give surprising results because higher counts are generally seen in youngstock.
Eight ways to keep clients' youngstock worms controlled:
For further information on worming together with some equine specific CPD visit: https://blog.vetsupportplus.com/
Richard Hepburn MRCVS has launched what is thought to be the world's first equine gastric ulcer study, designed to improve understanding and knowledge of ulceration in performance horses.
Mr Hepburn is conducting the InnerVision study of performance horses, which is being championed by the University of Liverpool, as part of his PhD.
21 appointed practices across the UK are participating in the study, and with each practice scoping between 10 and 20 animals, it will include well over 200 performance horses. Mr Hepburn said: "Gastric ulceration in sports horses is poorly understood, especially compared with racehorses. But what we do know is that it's a very important factor in the performance and well-being of many horses in training and competition."
2012 Paralympic Gold medallist Deb Criddle MBE also attended the launch event. She explained the difference that regular gastroscopy and ulcer management of Paralympic team horses had made to her success. Speaking about her Beijing ride, Pavaroti, she said: "If it weren't for the diagnosis and treatment of Pavaroti's ulcers I don't know what we'd have done. I would probably have had to withdraw him from training, so it made the difference between our partnership continuing or not".
Mr Hepburn expects a prevalence of approximately 60% and, keen to increase understanding of glandular ulceration, participants are being tasked to scope all areas of the stomach, pylorus and duodenum to ensure that every incidence of ulceration is diagnosed and recorded.
He says he is particularly eager to find out more about glandular disease, which hitherto has had little research: "Glandular disease appears to have a very different aetiology to squamous ulceration, and often presents with different signs. We also believe that prevalence of glandular ulceration is most common in sports horses."
"We hope that publication of this study will help all equine vets in their work with performance horses and the quest to prevent and manage equine ulcers," he added.
Merial is supporting the study with management assistance.
Feel Good Colic Rectals is a 20-minute online guide that uses state-of-the-art 3D modelling technology to allow you to visualise an examination of the normal equine abdomen, and to demonstrate how to differentiate abdominal abnormalities during a rectal examination.
The video features leading colic experts Professor Debra Archer BVMS PhD CertES (Soft Tissue) DipECVS MRCVS, head of equine surgery at the University of Liverpool, and Rachael Conwell BVetMed CertEM(IntMed) DECEIM MRCVS, European specialist in equine internal medicine.
To be in with a chance of winning one of 30 rectal tops, watch Feel Good Colic Rectals at www.boehringer-academy.co.uk, then answer two multiple choice questions.
This, say the researchers, is the first time in a UK field setting that the effect of early-life exposures, in particular exercise and turn out, on later-life milestones and race performance in Thoroughbreds has been comprehensively evaluated.
The findings can be applied at stud farms to help retain Thoroughbreds within the industry and achieve their athletic potential - outcomes that align with priorities of the Horse Welfare Board’s strategy to support the welfare of horses bred for racing.
The research team, led by Rebecca Mouncey MRCVS, a Post-Doctoral Research Fellow at the RVC, followed 129 flat race bred Thoroughbred foals, born in 2019 and 2020 on six stud farms across the UK, from birth into training for racing.
Each dam’s reproductive history, and details of her health and management during pregnancy were collected, as were daily records of the foal’s health and management from birth until they left the stud farm.
Race performance records up to the end of their fourth year of life were collated from racing industry databases.
The team then used statistical modelling to evaluate relationships between gestational exposures and early-life experiences and whether or not horses entered training and their subsequent race performance.
Findings suggested that the use of more extensive turnout practices during the first six months of life and later weaning benefited the attainment of career milestones, productivity (the number of races) and financial returns (total prizemoney won).
The main findings were:
The findings demonstrate that the first six months of life is a critical period of development in Thoroughbreds, during which it is essential that turnout and weaning practices provide sufficient opportunity for positive tissue adaptation and optimal development.
Breeders are therefore encouraged to maximise turnout whenever possible, and to consider weaning after this critical period.
https://www.rvc.ac.uk/research/projects/veeph/early-life-determinants-of-performance-and-the-economics-of-thoroughbred-breeding
A European study undertaken in horses to evaluate the efficacy of the key anthelmintic molecules fenbendazole, pyrantel, ivermectin and moxidectin in treating equine cyathostomins, has confirmed that resistance is developing against all the molecules with the exception of moxidectin.
Resistance to fenbendazole was highlighted as a particular issue with 80% of the yards tested in the UK and Germany showing resistance. Resistance to pyrantel also proved to be increasingly prevalent while cases of ivermectin resistance were emerging.
The Fort Dodge-sponsored study, the largest of its kind so far undertaken, took place during 2008 and was led by scientific teams from veterinary faculties in Italy and Germany. It was based on Faecal Egg Count Reduction Tests (FECRTs) of 1,704 horses at 102 yards in Italy, Germany and the UK. The calculation of FECR data was performed employing bootstrap analysis of group arithmetic means.
The study concluded that:
According to Dr Donato Traversa from the University of Teramo, Italy, who headed up the field work, the results confirm that single and even multiple drug resistance in equine cyathostomins is an increasing challenge in all three countries with resistance to fenbendazole and pyrantel a particular concern.
He said: "Our research highlights the necessity for vets, owners and managers to use those anthelmintic molecules that remain most effective in a manner which preserves their efficacy for as long as possible."
Professor Georg von Samson Himmelstjerna from Hannover University of Veterinary Medicine, which participated in the research, added: "Given the strong impact that resistant cyathostomins are likely to have on horse welfare, future parasite control plans should be based on integrated measures, involving both the correct use of anthelmintics, such as administering the correct dosing according to the animals weight, and only using products in the species for which it is licensed, as well as other approaches such as adequate pasture hygiene, low stocking rates and mixed grazing with other animals.
"We call on all concerned with equine health and welfare to take an active role in planning and monitoring effective worm control programs."
Jonathon is an RCVS & EBVS European Specialist in Veterinary Diagnostic Imaging, with a particular interest in MRI of the distal limb and has published scientific work on this subject, among others.
With the increase in availability and accessibility to CT for horses, VetCT says this hot topic will be well received by equine vets at all levels of experience.
VetCT’s Equine Teleradiology Manager, Charlotte Graham, said: “We can guarantee a highly engaging talk with plenty of useful tips on case selection for each modality as well as some interesting discussions in the Q&A session.”
To register for the webinar on 18th April and receive links to recordings of this and previous webinars in the 2023 series, sign up here: https://vetct.zoom.us/webinar/register/WN_zkctYZYWRUmRVIFTxrvvsA
www.vet-ct.com
IVC says the new brand will allow better communication for equine teams within the IVC Evidensia group as well as collaboration with the wider equine world.
IVC Evidensia Equine Vets range from graduates to European Specialists, working in both dedicated equine and mixed practice, with all practices supported by the four large equine veterinary referral hospitals in the UK: Donnington Grove Veterinary Group, Fyrnwy Equine Group, Oakham Veterinary Hospital and Pool House Equine.
IVC says the brand's mission is to put the welfare of horses at the heart of everything it does, to providing outstanding continuity of care for all equine species and breeds across the network, to be at the forefront of continual professional development, supporting and facilitating the development of clinical and leadership skills across all their equine teams, and to build the leading network for equine veterinary care across Europe.
Richard Stephenson, Chair of the IVC Evidensia Equine Clinical Board, said: "Our network brings together all forms of equine work from ambulatory practice to some of leading UK equine referral centres.
“It gives support to all our staff in their careers. We facilitate clinical development from the graduate academy, through intern training, residencies and training up to European Diplomat level.
“We provide coaching and leadership, flexible roles and friendly, inclusive teams.”
For more information, visit https://www.ivcevidensia.co.uk/Equine or stand B01 at BEVA 2021 congress.
The app gives users the ability to find information on over 1000 animal medicine listings included on the compendium website; with the complete datasheets available for viewing.
The new app also allows you to scan datamatrix barcodes on veterinary medicinal product packaging to take you straight to important product information. You can also search by medication, manufacturer or GTIN.
Dawn Howard, NOAH’s Chief Executive said: "The NOAH Compendium is the recognised industry reference, and it is essential we fully utilise the information offered in the compendium with modern technology, whilst protecting the integrity and respect that it holds.
"The website, which we relaunched earlier this year, has had over 8.5 million views to date. We feel this app serves as a great addition to this modern method of accessing data – meaning users are no longer reliant on internet access to obtain the information they need.
"As an organisation, we will continue to embrace new technologies to ensure animal medicine is used correctly and responsibly in the UK. The launch of this new app goes towards ensuring all those who prescribe or use animal medicines have access to the latest technical information available for companion and farm animals when they need it."
The objectives of the study1 were to assess the impact of the pandemic on the management of laminitis susceptible horses and ponies, to identify challenges faced in implementing COVID-19 based guidance, and to ascertain areas of decision making and policy development which could undergo improvement in future pandemic or emergency scenarios.
Lead author Ashely Ward, a PhD student at SRUC said: "We discovered that lockdown-associated factors had the potential to compromise the welfare of horses and ponies at risk of obesity and laminitis.
“These included: disparate information and guidance, difficulties enacting public health measures in yard environments, and horses having reduced exercise during the pandemic.
"Our conclusion was that guidelines should be developed for the care of horses and ponies at risk through collaborative input from veterinary and welfare experts. This would help to reduce the negative impacts of future lockdown events in the UK.”
Clare Barfoot RNutr, Marketing and Research and Development Director at Spillers said: “This work carries important recommendations to reduce equine welfare risks during any future lockdowns.
“This summer our primary focus has been on helping horse owners keep their horses at a healthy weight to reduce the risks associated with obesity, in particular laminitis. Until formal guidelines are developed we hope our range of practical advice, available online and via our Care-Line will help, should there be another lockdown."
The study was conducted in tandem with research looking at how the challenges brought about by the Covid-19 lockdown affected horse on the human/animal interaction. The conclusion, disseminated by SRUC last week, concluded that the coronavirus pandemic had a negative impact on the mental health and wellbeing of horse owners. https://www.sruc.ac.uk/all-news/horse-power-helps-owners-through-lockdown
The Government's updated Exotic Animal Disease Contingency Plan was laid in Parliament today.
The revised plan is produced by Animal Health for Defra, and includes changes which have been subject to formal public consultation. This includes a framework response plan for dealing with exotic animal diseases and plans for responding to specific diseases including Foot and Mouth Disease, Avian Influenza and Newcastle Disease.
The changes to the plan reflect lessons identified from the incidents handled during 2008 and address recommendations made in Sir Iain Anderson's review of the 2007 outbreak of Foot and Mouth Disease and feedback from the public consultation.
Jane Kennedy, Minister for Farming and the Environment said: "An animal disease outbreak can be devastating for those concerned. Defra remains totally committed to ensuring we learn lessons from our experience of outbreaks, so that we can make sure we respond effectively in future".
The Contingency Plan is subject to ongoing revision based on the latest scientific advice, developments in policy, comments from stakeholders and operational partners together with the lessons identified from disease outbreaks. It can be accessed here:www.defra.gov.uk/animalh/diseases/control/contingency/index.htm
Genitrix has announced that HY-50 Vet®, a sodium hyaluronate treatment for equine joints, has now been authorised for intravenous (IV) use.
Available until now for intra-articular (IA) use only, the company says HY-50 delivers the highest concentration of sodium hyaluronate on the market for the treatment of non-infectious joint inflammation and the enhancement of joint function.
Genitrix also says that, as IV application requires less specialist preparation than IA, HY-50 is now a practical solution for mixed practices with a smaller equine case load. Injected intravenously, the product will also benefit horses with multiple joint injuries.
HY-50 is presented in a 3 ml pre-loaded syringe, delivering 50 mg of sodium hyaluronate. It costs £55.50.
Rob Watkins, Marketing Director of Genitrix, said: "The efficacy of sodium hyaluronate is well established and we're delighted to be able to offer the IV route of administration. We know it will meet a real need in the market for a lameness treatment which is proven and simple to administer."
"Perhaps most importantly, in these financially difficult times, the high concentration of the product makes it a cost-effective approach compared with competitive products. We believe it will offer an affordable treatment option for owners who are anxious to treat their horses but may be discouraged by the high cost of many treatments."
For further information, see http://www.genitrix.co.uk/ or ring 01403 786345.
Consistent with previous surveys, lameness was shown to be more likely to be caused by conditions such as osteoarthritis in the limb rather than problems in the foot.
Blue Cross carries out NEHS in May each year in partnership with the British Equine Veterinary Association (BEVA). It is sponsored by Dodson & Horrell and Zoetis and supported by the UK’s leading equestrian organisations and charities.
This year saw a 14% increase in participation compared to 2015, with survey records returned for almost 16,751 horses, ponies, donkeys and mules and 5635 people taking part. Most horses were kept in livery or a private yard and used for leisure and hacking.
Lameness has been consistently seen as the most common syndrome affecting horses in the NEHS results year on year. In the latest survey a total of 32.9% (24.4% in 2015) of horses and ponies with health problems were recorded as lame. Overall, as in previous years, lameness in the limb was more common than lameness caused by problems in the foot.
A breakdown of the types of lameness revealed that 47.4% were recorded as suffering from proximal limb lameness, 31.9% from causes of foot lameness other than laminitis and 20.7% from laminitis. Degenerative joint disease (including foot and proximal limb) was the most frequently reported single cause of lameness (41.2% of all lameness) and the most frequently reported joint affected by DJD was the hock (15.3% of all lameness).
Reports of foot lameness (excluding laminitis) more than doubled this year at 10.5% (4.5% in 2015) of all syndromes reported with pus in the foot being the most frequently recorded problem. This could possibly be attributed to the persistent wet weather during and prior to the survey, which can increase susceptibility to the condition.
Josh Slater from the Royal Veterinary College, who is a member of BEVA’s Health & Medicines Committee and analysed the NEHS data, said: "The data gleaned from the survey remains consistent year on year, confirming the reliability of our findings for benchmarking, referencing and research. This year’s increase in overall lameness may be in part attributed to the higher incidence of pus in the foot but may also be because owners are becoming more aware of lameness issues. Ongoing research on lameness has generated significant media coverage over the past year, helping to raise understanding of the importance of accurate diagnosis and treatment both from welfare and performance perspectives."
The six most notable disease syndromes identified in the 2016 National Equine Health Survey are:
Gemma Taylor, Education Officer at Blue Cross said: "The significant increase in participation again this year shows that owners and keepers of horses are really getting behind the survey and recognising its importance in safeguarding the future health and of the UK’s horses. Over the past year NEHS data has been referred to in leading equestrian and veterinary media, showing its credibility as a valuable benchmarking reference."
The 2016 NEHS survey results are now available. To download a copy visit http://www.bluecross.org.uk/nehs2016results and to register for next year’s survey please visit www.bluecross.org.uk/nehs
Norbrook Laboratories has launched powder and paste versions of Noroquin - its glucosamine-based supplement range - for horses.
Noroquin contains the active ingredients glucosamine, chondrotin sulphate, manganese sulphate, zinc sulphate, absorbic acid and N-Acetyl-D-Glucosamine, designed to maintain healthy cartilage, promote joint management and keep horses mobile.
Michelle Jones, Brand Manager at Norbrook said: "In recent years, horses are increasingly competing longer which means maintaining the longevity of the horse is vitally important for long term success. 60% of lameness is related to osteoarthritis and is regarded as the major cause of disability in the athletic horse.
"With increasing reliability on nutritional supplements and concerns from horse owners about their aging horse, our Noroquin for Horses range can be offered as alternative to traditional pain management products indicated for musculoskeletal ailments or alongside them as a completely safe addition to a joint management programme."
Michelle added: "The Noroquin paste for horses is a highly palatable apple flavored paste that can be fed directly to the horse as a tasty treat and offers an alternative to traditional methods while the Noroquin powder for Horses is a highly palatable powder that can be mixed with food. The product is available in handy single-use sachets for accurate dosing and waterproof 1kg tubs."
Noroquin Powder and Paste for Horses joins the newly launched tasty tablets for dogs and cats and powder for cats in the Noroquin range. It is available from wholesalers.
Equipalazone is most commonly used to treat lameness in equines and can be prescribed as a treatment for osteoarthritic conditions, acute and chronic laminitis, bursitis and carpitis as well as to reduce post-surgical soft tissue reaction.
The new apple-flavoured version, which contains no added sugar, is presented in 1.5g sachets which are added to feed. The existing unflavoured product is still available as Equipalazone Original.
Dechra Brand Manager Emma Jennings said: “The new apple flavoured Equipalazone is the same tried and trusted popular product that vets have been using for many years but the enhanced apple flavour should improve compliance amongst even the fussiest of feeders.
"Equipalazone has been a best-selling treatment delivering powerful pain relief since we brought it to the market as the first microencapsulated phenylbutazone more than 45 years ago. The new apple flavoured presentation will give vets even more choice when it comes to providing pain relief and anti-inflammatory treatment for equine conditions."
For more information visit www.dechra.co.uk.